was read the article
array:23 [ "pii" => "S2173572715000247" "issn" => "21735727" "doi" => "10.1016/j.medine.2014.11.001" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "747" "copyrightAnyo" => "2014" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Med Intensiva. 2015;39:234-43" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8509 "formatos" => array:3 [ "EPUB" => 196 "HTML" => 6273 "PDF" => 2040 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210569114002587" "issn" => "02105691" "doi" => "10.1016/j.medin.2014.11.004" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "747" "copyright" => "Elsevier España, S.L.U. and SEMICYUC" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Med Intensiva. 2015;39:234-43" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 96486 "formatos" => array:3 [ "EPUB" => 321 "HTML" => 63059 "PDF" => 33106 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">REVISIÓN</span>" "titulo" => "Hiponatremias en el paciente neurocrítico: enfoque terapéutico basado en la evidencia actual" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "234" "paginaFinal" => "243" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Hyponatremia in the neurocritical care patient: An approach based on current evidence" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1538 "Ancho" => 1937 "Tamanyo" => 294524 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Algoritmo terapéutico de las hiponatremias en el paciente neurocrítico.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "W. Manzanares, I. Aramendi, P.L. Langlois, A. Biestro" "autores" => array:4 [ 0 => array:2 [ "nombre" => "W." "apellidos" => "Manzanares" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Aramendi" ] 2 => array:2 [ "nombre" => "P.L." "apellidos" => "Langlois" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Biestro" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173572715000247" "doi" => "10.1016/j.medine.2014.11.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572715000247?idApp=WMIE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569114002587?idApp=WMIE" "url" => "/02105691/0000003900000004/v2_201504190201/S0210569114002587/v2_201504190201/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2173572715000259" "issn" => "21735727" "doi" => "10.1016/j.medine.2014.11.002" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "748" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Med Intensiva. 2015;39:244-50" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6298 "formatos" => array:3 [ "EPUB" => 209 "HTML" => 5012 "PDF" => 1077 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Transcranial Doppler ultrasound in the diagnosis of brain death. Is it useful or does it delay the diagnosis?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "244" "paginaFinal" => "250" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Doppler transcraneal en el diagnóstico de la muerte encefálica. ¿Es útil o retrasa el diagnóstico?" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2199 "Ancho" => 2169 "Tamanyo" => 396725 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Middle cerebral artery showing a strongly systolic pattern with minimum diastolic flow, consistent with precerebral circulatory arrest. Pulsatility index 2.90, reflecting high intracranial pressure.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Escudero, J. Otero, B. Quindós, L. Viña" "autores" => array:4 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Escudero" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Otero" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Quindós" ] 3 => array:2 [ "nombre" => "L." "apellidos" => "Viña" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210569114002599" "doi" => "10.1016/j.medin.2014.11.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569114002599?idApp=WMIE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572715000259?idApp=WMIE" "url" => "/21735727/0000003900000004/v3_201509260116/S2173572715000259/v3_201509260116/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S217357271500017X" "issn" => "21735727" "doi" => "10.1016/j.medine.2015.03.004" "estado" => "S300" "fechaPublicacion" => "2015-05-01" "aid" => "698" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Med Intensiva. 2015;39:222-33" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3238 "formatos" => array:3 [ "EPUB" => 205 "HTML" => 2275 "PDF" => 758 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "222" "paginaFinal" => "233" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Grado de adherencia al tratamiento antivírico recomendado durante la pandemia y periodo pospandémico de gripe A (H1N1)pdm09 en 148 unidades de cuidados intensivos españolas" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1528 "Ancho" => 3261 "Tamanyo" => 230945 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Adjusted patient survival (Cox regression analysis) according to adherence to the treatment recommendations in both study periods.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Canadell, I. Martín-Loeches, E. Díaz, S. Trefler, S. Grau, J.C. Yebenes, J. Almirall, M. Olona, F. Sureda, J. Blanquer, A. Rodriguez" "autores" => array:12 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Canadell" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Martín-Loeches" ] 2 => array:2 [ "nombre" => "E." "apellidos" => "Díaz" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Trefler" ] 4 => array:2 [ "nombre" => "S." "apellidos" => "Grau" ] 5 => array:2 [ "nombre" => "J.C." "apellidos" => "Yebenes" ] 6 => array:2 [ "nombre" => "J." "apellidos" => "Almirall" ] 7 => array:2 [ "nombre" => "M." "apellidos" => "Olona" ] 8 => array:2 [ "nombre" => "F." "apellidos" => "Sureda" ] 9 => array:2 [ "nombre" => "J." "apellidos" => "Blanquer" ] 10 => array:2 [ "nombre" => "A." "apellidos" => "Rodriguez" ] 11 => array:1 [ "colaborador" => "in representation of the GETGAG" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210569114001430" "doi" => "10.1016/j.medin.2014.06.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569114001430?idApp=WMIE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357271500017X?idApp=WMIE" "url" => "/21735727/0000003900000004/v3_201509260116/S217357271500017X/v3_201509260116/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Hyponatremia in the neurocritical care patient: An approach based on current evidence" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "234" "paginaFinal" => "243" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "W. Manzanares, I. Aramendi, P.L. Langlois, A. Biestro" "autores" => array:4 [ 0 => array:4 [ "nombre" => "W." "apellidos" => "Manzanares" "email" => array:1 [ 0 => "wmanzanares@adinet.com.uy" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "I." "apellidos" => "Aramendi" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "P.L." "apellidos" => "Langlois" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "A." "apellidos" => "Biestro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Cátedra de Medicina Intensiva, Centro de Tratamiento Intensivo, Hospital de Clínicas, Facultad de Medicina, Universidad de la República (UdeLaR), Montevideo, Uruguay" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hôpital Fleurimont, Centre Hospitalier Universitaire de Sherbrooke, Département d’Anesthésie-Réanimation, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Québec, Canada" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hiponatremias en el paciente neurocrítico: enfoque terapéutico basado en la evidencia actual" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2515 "Ancho" => 3267 "Tamanyo" => 486173 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Therapeutic algorithm for hyponatremia in the neurocritical patient.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Hyponatremia is defined as a serum sodium concentration of <136<span class="elsevierStyleHsp" style=""></span>mmol/l, and is the most common electrolyte disorder in hospitalized patients (affecting 15–20% of all individuals requiring hospital admission).<a class="elsevierStyleCrossRefs" href="#bib0305"><span class="elsevierStyleSup">1,2</span></a> Likewise, hyponatremia is a mortality predictor in critical patients. In this regard, Stelfox et al.<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">3</span></a> have shown that hyponatremia acquired in the Intensive Care Unit (ICU) increases hospital mortality by 16–28% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). More recently, Sturdik et al.<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">4</span></a> have demonstrated that an age of over 65 years, the presence of dilutional hyponatremia, and its inadequate correction are three independent risk factors associated to increased hospital mortality in hyponatremic patients. Corona et al.,<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">5</span></a> in a systematic literature review and metaanalysis including 80 randomized clinical trials (RCTs), showed hyponatremia–even when mild–to be associated to a significant increase in mortality in the ICU (RR: 2.60; 95%CI: 2.31–2.93, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.0001).<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">5</span></a> Likewise, inadequate treatment of this electrolyte disorder, failing to observe the required correction range (overcorrection), as well as insufficient treatment, imply added risk that further worsens the prognosis of critical patients with hyponatremia.<a class="elsevierStyleCrossRefs" href="#bib0330"><span class="elsevierStyleSup">6,7</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In neurocritical patients, hyponatremia is also the most common electrolyte disorder, having been reported in up to 50% of all cases of serious neurological injury.<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">8</span></a> Among the acute brain conditions, severe traumatic brain injury (TBI) and aneurysmal subarachnoid hemorrhage (SAH) are those with the highest incidence of hyponatremia. In this regard, Sherlock et al.<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">9</span></a> showed hyponatremia to be more frequent in patients with hypophyseal disease (5/81; 6.25%), TBI (44/457; 9.6%) and intracranial tumors (56/355; 15.8%).<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">9</span></a> In their study the authors found that among 316 patients with SAH, 179 (56.6%) developed hyponatremia, which proved severe (natremia <130<span class="elsevierStyleHsp" style=""></span>mmol/l) in 62 cases (19.6%). In SAH, hyponatremia can be due to different causes, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), so-called cerebral salt wasting (CSW)–also known as renal salt wasting–and pressure natriuresis or acute corticosteroid deficiency (hypocortisolism).<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">10–13</span></a> Up until now, CSW has been regarded as the most frequent cause of hyponatremia in the evolutive course of aneurysmal SAH, though recently this has been strongly questioned. However, on the basis of current knowledge, the differential diagnosis between SIADH and CSW is often difficult to establish, and both syndromes moreover have been suggested to be part of one same disease condition–manifesting successively in the same patient.<a class="elsevierStyleCrossRefs" href="#bib0350"><span class="elsevierStyleSup">10,11</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Considering the above, the present review was carried out to provide an update on the etiological and physiopathological aspects of hyponatremia in the neurocritical patient, placing special emphasis on the treatment strategies adjusted to current evidence.</p><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Hypoosmolarity and neuronal adaptation mechanisms</span><p id="par0020" class="elsevierStylePara elsevierViewall">Hyponatremia/hypoosmolarity is a primary cause of water entry to the cells, resulting in an increase in cell volume (volumetric variation secondary to osmotic change).<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">14</span></a> This change in turn triggers a volume-regulating mechanism called regulatory volume decrease,<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">15</span></a> characterized by a rapid potassium, chloride and sodium outflow phase with the purpose of quickly “buffering” the osmotic change, and a second outflow phase of organic osmolytes (“non-perturbing” osmolytes) which accumulate in the neurons without producing deleterious effects upon cell structure and function (cytoprotective function). These compensating mechanisms are incomplete in acute hyponatremia (evolution under 48<span class="elsevierStyleHsp" style=""></span>h) and complete in chronic hyponatremia (evolution longer than 48<span class="elsevierStyleHsp" style=""></span>h). In the presence of cell swelling, a first phase (called the rapid phase) is observed, involving osmolyte outflow, followed by a second phase (or slow phase) characterized by inhibition of the synthesis of these osmolytes.<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">16</span></a> However, in acute neurological injury these protective mechanisms carried out by the neuroglia in response to plasma hypotonicity are altered. Likewise, the increase in circulating antidiuretic hormone (ADH) levels observed in the two characteristic conditions (CSW and SIADH) results in action upon the V1a receptors of vascular smooth muscle. The stimulation of these receptors generates vasoconstriction independent of the endothelium, due to an increase in the calcium levels through activation of the phosphatidylinositol-bisphosphonate cascade.<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">17</span></a> This cerebral vasoconstrictor effect reduces cerebral blood flow, oxygen supply to the astroglia, and the production of ATP and phosphocreatine.<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">17</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Etiology and physiopathology</span><p id="par0025" class="elsevierStylePara elsevierViewall">Cerebral salt wasting and SIADH have been defined as the most common causes of hyponatremia in the neurocritical patient.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">18,19</span></a> However, there are other less prevalent etiologies, such as the hypervolemic presentations and pressure natriuresis, which also must be discarded in order to establish an adequate diagnostic strategy.<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">20</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Likewise, despite the notorious interest in these two syndromes in recent years, the differential diagnosis between CSW and SIADH is often a genuine challenge, since the clinical manifestations are not always conclusive, and the laboratory test information is frequently confusing. In this regard, the current tendency is to classify both conditions under one same disease entity.<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">16,21</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall"><a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a> shows the main characteristics allowing us to establish a differential diagnosis between CSW and SIADH.<a class="elsevierStyleCrossRefs" href="#bib0310"><span class="elsevierStyleSup">2,8,12,16</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">Classically, the presence of hypovolemia has been regarded as the distinctive feature of CSW, though it is difficult to diagnose in the neurocritical patient.</p><p id="par0045" class="elsevierStylePara elsevierViewall">However, a series of methods are now available for assessing volemia and cardiac output in the critical patient. With the introduction of hemodynamic monitoring devices fundamented upon arterial pulse wave analysis (PiCCO<span class="elsevierStyleSup">®</span>, PulseCO<span class="elsevierStyleSup">®</span>, FloTrac/Vigileo<span class="elsevierStyleSup">®</span> and MostCare<span class="elsevierStyleSup">®</span>, among others), it has become simple to estimate these parameters on a continuous basis.<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">22</span></a> The use of such invasive techniques provides adequate results that are better than static preload values such as central venous pressure or pulmonary artery wedge pressure.<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">23</span></a> The use of a device of this kind may be necessary in order to obtain a good evaluation of patient volemia, and therefore an adequate diagnosis of the type of hyponatremia involved. Likewise, a noninvasive technique widely used in the ICU, such as ultrasound, can prove useful for estimating volemia in patients of this kind.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Recently, Gritti et al.<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">24</span></a> have evaluated the cumulative sodium balance with the purpose of diagnosing CSW in 35 neurocritical patients. In these individuals, the authors showed that the risk of developing hypovolemia is increased 7.1-fold (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001) in the presence of a negative sodium balance. Likewise, the multivariate analysis identified a negative water balance and a negative sodium balance of >2<span class="elsevierStyleHsp" style=""></span>mEq/kg as independent risk factors for hypovolemia. A negative sodium balance was therefore identified as a useful tool for establishing a differential diagnosis between CSW and SIADH in neurocritical patients.<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">24</span></a></p></span></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Hyponatremia in specific clinical scenarios</span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Subarachnoid hemorrhage</span><p id="par0055" class="elsevierStylePara elsevierViewall">Hyponatremia is highly prevalent in patients with SAH, being described in 10–50% of the cases, particularly in high-grade SAH, in the presence of anterior circulation aneurysms, and in hydrocephalia. In 2005, Kao et al.<a class="elsevierStyleCrossRef" href="#bib0425"><span class="elsevierStyleSup">25</span></a> found 22.9% of the case of hyponatremia to be secondary to CSW, while 35.4% corresponded to SIADH. In an elegant and recent study, Hannon et al.<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">26</span></a> prospectively evaluated the etiology of hyponatremia in a sample of 100 patients with SAH, based on clinical assessment and the determination of serum cortisol, arginine, vasopressin and brain natriuretic peptide. In their study,<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">26</span></a> the authors identified SIADH as the predominant cause (71.4%), while hypocortisolism accounted for 8.2% of the cases of hyponatremia. The remaining 20.4% of the cases were in turn attributed to hypovolemia or to the type of fluid administered. However, the most significant finding of the mentioned study was the absence of cases consistent with CSW.<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">26</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Nakagawa et al.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">27</span></a> have recently demonstrated that the early administration of fludrocortisone acetate can reduce the risk of hyponatremia (26% versus 16%) and of symptomatic vasospasm (18.5% versus 6.1%) in SAH. These data could indicate the existence of an association between hyponatremia and the development of vasospasm, though further studies are needed to clarify this relationship.<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">27</span></a> Likewise, in SAH, triple H therapy (hypertension, hypervolemia and hemodilution) as an anti-vasospasm strategy promotes pressure natriuresis and the risk of hyponatremia.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Ischemic stroke</span><p id="par0065" class="elsevierStylePara elsevierViewall">The presence of hyponatremia in ischemic stroke has been proposed as a predictor of poor outcome, though the underlying etiopathogenesis is not fully clear. Huang et al.,<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">28</span></a> in 925 patients with a first episode of ischemic stroke, recorded an incidence of hyponatremia of 11.6%, which in turn was associated to a significant increase in mortality after three years (RR: 2.23; 95%CI: 1.30–3.82%). Likewise, Rodrigues et al.<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">29</span></a> recently identified the presence of hyponatremia in 16% of 565 stroke patients. In this population, hyponatremia was associated to a significant increase in hospital mortality (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.039) and in mortality after three months (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.001) and one year (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.001). A surprising observation was a greater incidence of urinary infection in the patients with hyponatremia. Lastly, hyponatremia associated to a first episode of ischemic stroke is an independent risk factor for the development of seizures, according to Wang et al.<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">30</span></a> (OR: 2.10) and Roivainen et al.<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">31</span></a> (OR: 3.26; 95%CI: 1.41–7.57).</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Traumatic brain injury</span><p id="par0070" class="elsevierStylePara elsevierViewall">Hyponatremia is highly prevalent in patients with severe TBI, where dysfunction of the hypothalamic–hypophyseal–adrenal axis is common,<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">32</span></a> having been described in 15–68% of the cases, with an incidence of hypopituitarism of 50%<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">33</span></a> in the course of the disorder. In severe TBI, hypopituitarism is more frequent in younger patients, as well as in those administered etomidate, propofol or fenobarbital.<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">32</span></a> The clinical manifestations include hypocortisolism, hyponatremia, hypoglycemia and arterial hypotension.<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">34</span></a> In clinical practice the systematic assessment of hypophyseal function has been recommended in patients with skull base fractures, diffuse axonal damage, and in cases of prolonged admission to the ICU. However, despite the high incidence of hypocortisolism, the existing evidence contraindicates the empirical use of corticosteroids as specific treatment for intracranial hypertension in TBI.</p><p id="par0075" class="elsevierStylePara elsevierViewall">The analysis of other causes of hyponatremia in TBI shows SIADH to account for 33% of the cases, presenting a particular association to subdural hematoma and focal contusions.<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">32–34</span></a> Likewise, SIADH often manifests during the second week of admission to the ICU and during the evolution of central or neurogenic <span class="elsevierStyleItalic">diabetes insipidus</span>–this being explained by the release of ADH stored in the axons of the neurohypophysis.<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">21</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">Lastly, it must be mentioned that in patients with severe TBI, hyponatremia may be secondary to the use of certain drugs such as 20% mannitol–administered as an osmotically active agent for the control of intracranial pressure (hypovolemic stimulus secondary to osmotic diuresis)–carbamazepine and desmopressin (iatrogenic hyponatremia), used for the treatment of the central <span class="elsevierStyleItalic">diabetes insipidus</span>.<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">32–34</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Neurosurgery</span><p id="par0085" class="elsevierStylePara elsevierViewall">In a retrospective analysis including 291 children subjected to tumor resection published by Hardesty et al.,<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">35</span></a> hyponatremia was present in almost 10% of the patients, and 5% met the previously established criteria of CSW.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Trans-sphenoidal surgery is one of the surgical procedures most commonly associated to hyponatremia, manifesting between 5 and 9 days after the operation, with a peak incidence on day 7. Such hyponatremia may be early (secondary to axonal degeneration and the massive release of ADH) or late (often secondary to adrenal gland insufficiency).<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">21</span></a> Jahangiri et al.,<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">36</span></a> in 1045 consecutive surgeries, recently recorded an incidence of hyponatremia of 3% in the preoperative period–a figure that increased to 16% in the postoperative period. In turn, 19% of the hyponatremia episodes were asymptomatic; the mean timing of appearance was day 4; and preoperative hypopituitarism was the only variable associated to an increased risk of postoperative hyponatremia. Likewise, hyponatremia was present in 15% of the cases requiring hospital admission. Lastly, the authors concluded that SIADH was the predominant syndrome in this population–CSW being exceptional.<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">36</span></a> In turn, Hussain et al.,<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">37</span></a> in 339 neurosurgical patients, recorded a 15% incidence of postoperative hyponatremia in the first 30 days after surgery. Of these episodes, 50% were regarded as mild, and hospital readmission proved necessary in 6.4% of the patients.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Treatment of hyponatremia</span><p id="par0095" class="elsevierStylePara elsevierViewall">Independently of the underlying etiology and of the fact that the physiopathology involved is not always clear, the presence of hyponatremia in neurocritical patients justifies grouping of the two classical hyponatremia-producing syndromes in one same treatment strategy.</p><p id="par0100" class="elsevierStylePara elsevierViewall">The treatment of hyponatremia recognizes central pontine myelinolysis as the most severe and feared complication, being related to overcorrection, while insufficient replacement may also be a cause of permanent brain damage.<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> For this reason, in neurocritical patients, the treatment of hyponatremia requires identification of its severity, duration (acute and chronic forms), patient volemia status, and the severity of the clinical condition. In these patients, and depending on the evolutive stage, the appearance of hyponatremia must be regarded as a genuine medical emergency requiring the immediate adoption of adequate treatment measures. The following sections analyze the management strategies referred to hyponatremia in different clinical scenarios, including hyponatremic encephalopathy and a number of critical neurological disorders.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Severe and symptomatic hyponatremia: hyponatremic encephalopathy</span><p id="par0105" class="elsevierStylePara elsevierViewall">Recently, the European Society of Intensive Care Medicine, in coordination with the European Society of Endocrinology and the European Renal Association-European Dialysis and Transplant Association, represented by the European Renal Best Practice, have published good clinical practice guides on the diagnosis and treatment of hyponatremia in critical patients.<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> In the case of severe and symptomatic hyponatremia (hyponatremic encephalopathy), these guides recommend the intravenous infusion of 150<span class="elsevierStyleHsp" style=""></span>ml of 3% hypertonic saline solution (HSS) over 20<span class="elsevierStyleHsp" style=""></span>min. This 3% HSS bolus is to be repeated in the next 20<span class="elsevierStyleHsp" style=""></span>min as long as the symptoms persist or if natremia fails to increase significantly. In this regard, dosing can be repeat up to two times or until a natremia increment of 5<span class="elsevierStyleHsp" style=""></span>mmol/l is achieved.<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> The infusion of 3% HSS is able to increase natremia by 1–2<span class="elsevierStyleHsp" style=""></span>mmol/h–reversion of the symptoms of hyponatremic encephalopathy (seizures, altered consciousness) requiring an increase of 4–6<span class="elsevierStyleHsp" style=""></span>mmol<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> (see <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0110" class="elsevierStylePara elsevierViewall">In a way similar to the recommendations of the European Society of Intensive Care Medicine/European Society of Endocrinology/European Renal Association-European Dialysis and Transplant Association, Sterns et al.,<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">20</span></a> in the presence of severe symptoms, recommend the administration of 100<span class="elsevierStyleHsp" style=""></span>ml of 3% HSS via the intravenous route during 10<span class="elsevierStyleHsp" style=""></span>min, with the possibility of repeating the dose three times if needed, in order to control the clinical condition. Although there are more conservative regimens comprising 6<span class="elsevierStyleHsp" style=""></span>mmol/day, it is important to emphasize that the natremia increment when the starting concentration is ≤120<span class="elsevierStyleHsp" style=""></span>mmol/l should not exceed 10<span class="elsevierStyleHsp" style=""></span>mmol/l during the first 24<span class="elsevierStyleHsp" style=""></span>h of 3% HSS administration–with a maximum increase of 8<span class="elsevierStyleHsp" style=""></span>mmol/l in the 24<span class="elsevierStyleHsp" style=""></span>h after obtaining a natremia level of 130<span class="elsevierStyleHsp" style=""></span>mmol/l.<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">12,20,38</span></a> Thus, the increase in serum sodium should not exceed 18<span class="elsevierStyleHsp" style=""></span>mmol/l in 48<span class="elsevierStyleHsp" style=""></span>h. Lastly, it must be taken into account that the correction of concomitant hypokalemia also favors the correction of hyponatremia, with the additional need to correct the hypoxemia in order to favor neuronal adaptation to the hypotonic damage.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Treatment of hyponatremia in the neurocritical patient</span><p id="par0115" class="elsevierStylePara elsevierViewall">The hyponatremia management strategy in neurocritical patients implies treatment of the underlying cause in parallel to management of hyponatremia per se. In current clinical practice in neurological ICUs, establishing a differential diagnosis between CSW and SIADH should no longer be seen as a crucial step for guiding treatment.<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">12,20</span></a> It has classically been considered that the treatment of CSW requires vigorous sodium administration in the form of 3% HSS, with the purpose of compensating natriuresis. In contrast, SIADH regards fluid restriction as the cornerstone of treatment, since the renal reabsorption of free water is increased in SIADH. However, this strategy is relatively contraindicated in patients with SAH, due to the high risk of vasospasm (level of evidence <span class="elsevierStyleSmallCaps">ii</span>). Likewise, other management measures that can be adopted in SIADH are the use of lithium, demeclocycline and furosemide (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><p id="par0120" class="elsevierStylePara elsevierViewall">In 2008, Sterns and Silver<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">12</span></a> introduced the concept of cerebral salt wasting, which assumes that in patients with severe brain injury, the presence of hyponatremia requires the administration of 3% HSS independently of the cause underlying the sodium disorder.<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">12</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">On the other hand, in neurocritical patients with high ADH and natriuretic peptide levels, the administration of isotonic saline solution generates the so-called desalination phenomenon,<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">39</span></a> which can worsen hyponatremia secondary to natriuresis, with the renal production of electrolyte-free water.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">3% Hypertonic saline solution</span><p id="par0130" class="elsevierStylePara elsevierViewall">To date, and despite the high prevalence of hyponatremia in neurocritical patients, no randomized clinical trials (RCTs) have evaluated different hypertonic fluids in the treatment of hyponatremia. Likewise, the existing evidence on the use of HSS is based on non-randomized trials; as a result, the posology and duration of treatment cannot be clearly defined.<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">40,41</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Three percent HSS can safely increase natremia without causing neurological, cardiac or renal alterations, and is often administered via a peripheral venous access, with a low risk of complications.<a class="elsevierStyleCrossRefs" href="#bib0500"><span class="elsevierStyleSup">40,41</span></a> This solution contains the minimum sodium concentration capable of exceeding the maximum osmolar concentration of urine. As a result, if 3% HSS constitutes the only replenishment source, natremia will always increase, since the desalination phenomenon is highly improbable.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Current evidence indicates that the continuous infusion of 3% HSS is safe in the presence of strict monitoring of patient natremia, complying with the correction ranges, and when the maximum target natremia is 155–160<span class="elsevierStyleHsp" style=""></span>mmol/l (permissive or therapeutic hypernatremia).<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">42</span></a> In this regard, Aiyagari et al.<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">43</span></a> reported a 52% mortality rate in severe hypernatremia defined as >160<span class="elsevierStyleHsp" style=""></span>mmol/l (induced or spontaneous), in a population of neurocritical patients. Likewise, Froelich et al.<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">44</span></a> showed the appearance of hypernatremia >155<span class="elsevierStyleHsp" style=""></span>mmol/l in neurocritical patients subjected to the continua perfusion of 3% HSS to be associated to the development of renal dysfunction, with creatininemia >1.50<span class="elsevierStyleHsp" style=""></span>mg/dl (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.01).</p><p id="par0145" class="elsevierStylePara elsevierViewall">Three percent HSS infusion can cause side effects such as hypernatremia, hyperchloremia, hyperchloremic metabolic acidosis, hypokalemia and acute renal failure<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">45</span></a> (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). On the other hand, an initial intravenous bolus may cause transient arterial hypotension, as well as hypervolemia and hemodynamic pulmonary edema. The administration of a solution of sodium lactate 0.5<span class="elsevierStyleHsp" style=""></span>M (osmolarity 1008<span class="elsevierStyleHsp" style=""></span>mOsm/l) with the purpose of reducing the episodes of intracranial hypertension in patients with TBI is able to correct natremia without producing hyperchloremia or metabolic acidosis, as recently demonstrated by Ichai et al.<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">46</span></a></p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Fludrocortisone acetate</span><p id="par0150" class="elsevierStylePara elsevierViewall">In 2005, the first systematic literature review and metaanalysis on the effects of corticosteroids in aneurysmal SAH and primary intracerebral hemorrhage, including 8 RCTs (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>256), evidenced no positive effect with the administration of fludrocortisone.<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">47</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall">Fludrocortisone acetate is a synthetic mineralocorticoid that favors the renal tubular reabsorption of sodium. It is able to reduce the natriuretic response, thereby preventing the appearance of hyponatremia.<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">48</span></a> On the other hand, thanks to its weaker glucocorticoid effect, fludrocortisone is associated to a lesser incidence of side effects compared with hydrocortisone. In 2009, a multidisciplinary committee recommended the use of fludrocortisone in patients with SAH who develop hyponatremia and are thus at a high risk of vasospasm. In turn, the Stroke Council of the American Heart Association<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">49</span></a> recommends the use of HSS and fludrocortisone as a reasonable strategy for the treatment of hyponatremia and the reduction of effective circulating volume in aneurysmal SAH. Likewise, in October 2010, the consensus conference of the Neurocritical Care Society on the management of aneurysmal SAH established that early treatment with fludrocortisone can be used to limit natriuresis (moderate quality evidence, weak recommendation).<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">50</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">However, it is necessary to point out that fludrocortisone acetate loses efficacy when hyponatremia is severe. In 2009, Nakagawa et al.,<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">51</span></a> in a series of 39 patients with aneurysmal SAH, found high atrial natriuretic peptide values to be associated to hyponatremia. The authors postulated that early treatment of the latter–including the use of fludrocortisone–would be able to inhibit the late ischemic neurological deficit, since the mentioned drug can reduce the incidence of symptomatic vasospasm. In this regard, they suggested that an increase in urine sodium levels is a good indicator for starting enteral fludrocortisone in the early stages of SAH.<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">51</span></a> At present, in neurocritical patients with osmotic diuresis and natriuresis (CSW), the recommended daily dose of fludrocortisone is 0.1–0.2<span class="elsevierStyleHsp" style=""></span>mg via the oral route, 2–3 times a day. This treatment is to be maintained until the normalization of natremia and volemia is–this often being achieved after 3–5 days of treatment. Prolonged fludrocortisone treatment increases the incidence of side effects such as hypokalemia, arterial hypertension and hydrostatic pulmonary edema (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). Likewise, mineralocorticoid escape is a well known phenomenon that conditions tolerance to its effects and a loss of action of the drug after administration periods of over one week.</p><p id="par0165" class="elsevierStylePara elsevierViewall">On the other hand, hydrocortisone has been shown to be effective for the control of natriuresis in patients with SAH and hyponatremia,<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">50</span></a> though the existing data are scarce, and further RCTs are needed to adequately assess the use of this strategy in neurocritical patients. Lastly, the combined use of hydrocortisone and fludrocortisone has not been shown to exert synergic effects in terms of sodium gain in this group of patients.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Vasopressin antagonists (vaptans)</span><p id="par0170" class="elsevierStylePara elsevierViewall">Two drugs of this class, tolvaptan and conivaptan, have been approved to date by the United States Food and Drug Administration (FDA) for the treatment of normovolemic and hypervolemic hyponatremia.<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">52</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">Conivaptan, administered via the intravenous route, is a receptor V1a and receptor V2 antagonist, and is the drug of choice in the hospital setting for those patients unable to tolerate the oral route. However, its use is limited to a maximum of four days,<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">53</span></a> and its effect is greater in the presence of hyponatremia and a high glomerular filtration rate (GFR). Likewise, the administration of conivaptan in intermittent doses has been found to be effective in increasing the renal excretion of free water–with the consequent correction of hyponatremia in neurocritical patients.<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">54</span></a> In effect, Murphy et al.<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">54</span></a> recorded a minimum increase in natremia of 6<span class="elsevierStyleHsp" style=""></span>mmol/l in up to 52% of the patients, while 69% of them showed a rise in natremia of 4<span class="elsevierStyleHsp" style=""></span>mmol/l after 72<span class="elsevierStyleHsp" style=""></span>h. More recently, Human et al.<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">55</span></a> conducted a retrospective evaluation of 124 neurocritical patients, and found the administration of an intravenous bolus dose of conivaptan to be able to produce a mean increase in natremia of 4<span class="elsevierStyleHsp" style=""></span>mmol/l.</p><p id="par0180" class="elsevierStylePara elsevierViewall">On the other hand, conivaptan has been shown to reduce intracranial pressure and increase natremia on a transient basis, without adverse effects, in patients with severe TBI.<a class="elsevierStyleCrossRef" href="#bib0580"><span class="elsevierStyleSup">56</span></a> In this sense it reflects the concept of reductive osmotherapy, in which there is no gain in solute but a decrease in solvent. On the other hand, this effect could also be related to inhibition of the V1a receptor, which intervenes in the expression of AQP4 aquaporin channels this being of fundamental importance in the development of brain edema in patients with severe TBI and stroke.<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">57,58</span></a> However, this requires confirmation by further studies. The current conivaptan dosage consists of a 20<span class="elsevierStyleHsp" style=""></span>mg intravenous loading dose administered over 30<span class="elsevierStyleHsp" style=""></span>min, followed by a continuous intravenous perfusion of 20–40<span class="elsevierStyleHsp" style=""></span>mg/day for a period of under four days.</p><p id="par0185" class="elsevierStylePara elsevierViewall">Tolvaptan in turn is a receptor V2 antagonist<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">59</span></a> that has shown clinical benefits by reducing hospital stay in patients with SIADH, as evidenced by the SALT-1 and SALT-2 trials carried out in North America and Europe, respectively.<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">60</span></a> In case reports, this drug has been found to be safe and effective in the treatment of hyponatremia associated to SIADH in severe TBI<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">60</span></a> and in patients with non-traumatic neurological damage, where the administration of a daily dose of 15<span class="elsevierStyleHsp" style=""></span>mg of tolvaptan has been seen to be as effective as conivaptan.<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">60</span></a> The currently recommended tolvaptan dose is 15<span class="elsevierStyleHsp" style=""></span>mg, which can be increased to 30–60<span class="elsevierStyleHsp" style=""></span>mg a day in cases of hyponatremia <135<span class="elsevierStyleHsp" style=""></span>mmol/l, or if the observed natremia increment is <5<span class="elsevierStyleHsp" style=""></span>mmol/day. Since the vaptans correct hyponatremia by facilitating free water elimination, it is important to evaluate the patient blood volume and avoid their use in individuals with hypovolemic hyponatremia. These drugs therefore might be indicated in neurocritical patients with hyponatremia, though for the time being their administration should be limited to patients in which conventional therapy has failed, or as coadjuvant treatment.<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">52</span></a></p><p id="par0190" class="elsevierStylePara elsevierViewall">The recent European guidelines do not advise the use of these drugs in neurocritical patients with SIADH and moderate to severe hyponatremia.<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> Lastly, these substances are contraindicated in patients with a glomerular filtration rate of <30<span class="elsevierStyleHsp" style=""></span>ml/min, and in the presence of previous liver disease.<a class="elsevierStyleCrossRefs" href="#bib0565"><span class="elsevierStyleSup">53,54</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Treatment of hyponatremia overcorrection</span><p id="par0195" class="elsevierStylePara elsevierViewall">In the case of accidental natremia overcorrection, with values of >10<span class="elsevierStyleHsp" style=""></span>mmol/l during the first 24<span class="elsevierStyleHsp" style=""></span>h, or of 8<span class="elsevierStyleHsp" style=""></span>mmol/l during day 2, it is possible to reinduce hyponatremia (according to the guides of the European Society of Intensive Care Medicine/European Society of Endocrinology/European Renal Association-European Dialysis and Transplant Association)<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">38</span></a> with the aim of avoiding central pontine myelinolysis. The following scheme can be used in cases of natremia overcorrection, particularly when the initial serum sodium value is 120<span class="elsevierStyleHsp" style=""></span>mmol/l<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">11,20,38</span></a>:</p><p id="par0200" class="elsevierStylePara elsevierViewall">The infusion of 3% HSS and of all treatments tending to reduce natriuresis should be interrupted.</p><p id="par0205" class="elsevierStylePara elsevierViewall">The infusion of 5% dextrose solution (3<span class="elsevierStyleHsp" style=""></span>ml/kg/h) as a means for administering electrolyte-free water is a useful management option.</p><p id="par0210" class="elsevierStylePara elsevierViewall">The administration of intravenous desmopressin (2–4<span class="elsevierStyleHsp" style=""></span>μg in 3 daily doses). It is important to mention that this drug is not indicated in patients with intracranial hypertension, due to the risk of increasing the brain edema.</p><p id="par0215" class="elsevierStylePara elsevierViewall">Hourly monitoring of natremia with the purpose of avoiding a decrease beyond the predetermined target value.</p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conclusion</span><p id="par0220" class="elsevierStylePara elsevierViewall">Hyponatremia is the most frequent electrolytic disturbance in neurocritical patients, and is a leading cause of morbidity–mortality if adequate and immediate treatment is not provided. The syndrome of inappropriate antidiuretic hormone secretion and CSW have been described as the two syndromes that most often explain the presence of hyponatremia associated to increased natriuresis in neurocritical patients. In these cases the evaluation of volemia allows us to establish a differential diagnosis between the two disease conditions–though in many patients such differentiation is a genuine challenge. However, recent evidence has questioned the existence of CSW as a cause of hyponatremia in aneurysmal SAH. Conceptually, the diagnosis of cerebral salt wasting seems more appropriate for defining hyponatremia in the neurocritical patient, since the reference treatment is always the same, regardless on the underlying cause: the administration of hypertonic saline solution. Likewise, in the neurocritical ICU, the treatment of hyponatremia depends on a number of factors such as the underlying disease process, the speed with which the condition develops, and patient volemia. Lastly, some alternative treatments have been studied, such as fludrocortisone and the vaptans, though conclusive evidence regarding their use is still lacking, and no definitive agreement has been reached regarding their indications.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Conflicts of interest</span><p id="par0225" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:9 [ 0 => array:3 [ "identificador" => "xres559365" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec575063" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres559364" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec575062" "titulo" => "Palabras clave" ] 4 => array:3 [ "identificador" => "sec0005" "titulo" => "Introduction" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0010" "titulo" => "Hypoosmolarity and neuronal adaptation mechanisms" ] 1 => array:2 [ "identificador" => "sec0015" "titulo" => "Etiology and physiopathology" ] ] ] 5 => array:3 [ "identificador" => "sec0020" "titulo" => "Hyponatremia in specific clinical scenarios" "secciones" => array:11 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Subarachnoid hemorrhage" ] 1 => array:2 [ "identificador" => "sec0030" "titulo" => "Ischemic stroke" ] 2 => array:2 [ "identificador" => "sec0035" "titulo" => "Traumatic brain injury" ] 3 => array:2 [ "identificador" => "sec0040" "titulo" => "Neurosurgery" ] 4 => array:2 [ "identificador" => "sec0045" "titulo" => "Treatment of hyponatremia" ] 5 => array:2 [ "identificador" => "sec0050" "titulo" => "Severe and symptomatic hyponatremia: hyponatremic encephalopathy" ] 6 => array:2 [ "identificador" => "sec0055" "titulo" => "Treatment of hyponatremia in the neurocritical patient" ] 7 => array:2 [ "identificador" => "sec0060" "titulo" => "3% Hypertonic saline solution" ] 8 => array:2 [ "identificador" => "sec0065" "titulo" => "Fludrocortisone acetate" ] 9 => array:2 [ "identificador" => "sec0070" "titulo" => "Vasopressin antagonists (vaptans)" ] 10 => array:2 [ "identificador" => "sec0075" "titulo" => "Treatment of hyponatremia overcorrection" ] ] ] 6 => array:2 [ "identificador" => "sec0080" "titulo" => "Conclusion" ] 7 => array:2 [ "identificador" => "sec0085" "titulo" => "Conflicts of interest" ] 8 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2014-09-16" "fechaAceptado" => "2014-11-11" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec575063" "palabras" => array:5 [ 0 => "Hyponatremia" 1 => "Neurocritically ill patient" 2 => "Cerebral salt wasting" 3 => "Syndrome of inappropriate antidiuretic secretion" 4 => "Hypertonic saline solution" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec575062" "palabras" => array:5 [ 0 => "Hiponatremias" 1 => "Paciente neurocrítico" 2 => "Cerebro perdedor de sal" 3 => "Secreción inadecuada de hormona antidiurética" 4 => "Cloruro de sodio hipertónico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">In the neurocritical care setting, hyponatremia is the commonest electrolyte disorder, which is associated with significant morbimortality. Cerebral salt wasting and syndrome of inappropriate antidiuretic hormone have been classically described as the 2 most frequent entities responsible of hyponatremia in neurocritical care patients. Nevertheless, to distinguish between both syndromes is usually difficult and useless as volume status is difficult to be determined, underlying pathophysiological mechanisms are still not fully understood, fluid restriction is usually contraindicated in these patients, and the first option in the therapeutic strategy is always the same: 3% hypertonic saline solution. Therefore, we definitively agree with the current concept of “cerebral salt wasting”, which means that whatever is the etiology of hyponatremia, initially in neurocritical care patients the treatment will be the same: hypertonic saline solution.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">En el paciente neurocrítico la hiponatremia es la distonía más frecuente, comportándose como un predictor pronóstico. Clásicamente, el cerebro perdedor de sal y la secreción inadecuada de hormona antidiurética han sido las 2 entidades responsables de explicar la mayor parte de los casos de hiponatremia en estos pacientes. Sin embargo, en virtud de la dificultad en establecer el estado de la volemia en el paciente crítico, el diagnóstico diferencial es con frecuencia difícil de establecer. Por otra parte, en el paciente neurocrítico el diagnóstico diferencial entre ambos síndromes no ha demostrado ser de utilidad debido a que el cloruro de sodio hipertónico es la piedra angular en el tratamiento de ambos cuadros, y la restricción hídrica con frecuencia está contraindicada. Es por ello que ha surgido el concepto de «cerebro falto de sal», lo cual traduce la necesidad del aporte de sodio como estrategia terapéutica en todos los casos.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Manzanares W, Aramendi I, Langlois PL, Biestro A. Hiponatremias en el paciente neurocrítico: enfoque terapéutico basado en la evidencia actual. Med Intensiva. 2015;39:234–243</p>" ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2515 "Ancho" => 3267 "Tamanyo" => 486173 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Therapeutic algorithm for hyponatremia in the neurocritical patient.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Source: Kirkman et al.,<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">2</span></a> Kirkman,<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">8</span></a> Yee et al.<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">16</span></a> and Hwang and Hwang.<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">21</span></a>" "tabla" => array:2 [ "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">CSW: cerebral salt wasting; PCP: pulmonary capillary pressure; CVP: central venous pressure; SIADH: inappropriate antidiuretic hormone secretion syndrome; ↑: increased; ↓: decreased; =: without changes.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CSW \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">SIADH \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Extracellular volume \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↓ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Normal or ↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Water balance \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Normal or ↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Sodium balance \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Normal or ↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Natriuresis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↑↑↑ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Body weight \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleMonospace">=</span> or ↓ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">= or ↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Dehydration \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Present \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Absent \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">PCP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↓ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleMonospace">=</span> or ↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">CVP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↓ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleMonospace">=</span> or ↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Plasma/urine osmolarity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↓ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↑ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Hematocrit \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↑ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleMonospace">=</span> or ↓ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Albuminemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↑ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleMonospace">=</span> or ↓ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Azotemia/creatininemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↑ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Normal \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Uricemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↓ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">↓ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Serum potassium \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleMonospace">=</span> or ↑ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">= or ↓ \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab902820.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Conventional schematic representation of cerebral salt wasting (CSW) and syndrome of inappropriate antidiuretic hormone secretion (SIADH).</p>" ] ] 2 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">CSW: cerebral salt wasting; ICH: intracranial hypertension; i.v.: intravenous route; SIADH: syndrome of inappropriate antidiuretic hormone secretion.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Strategy \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Usual dose \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Side effects \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Indications \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">3% Hypertonic saline solution<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">20,38,40–45</span></a>: sodium 513<span class="elsevierStyleHsp" style=""></span>mmol/l; chloride 513<span class="elsevierStyleHsp" style=""></span>mmol/l; osmolarity 1026<span class="elsevierStyleHsp" style=""></span>mOsm/l \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The usual doses for treatment of the symptomatic and asymptomatic forms are shown in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Overcorrection, thrombosis, phlebitis, hypervolemia, hyperchloremia, acidosis, lung edema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Symptomatic acute or chronic hyponatremia. Osmotherapy in ICH. Osmotic diuresis due to natriuresis and decreasing natremia. Permissive or therapeutic hypernatremia \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Fludrocortisone<a class="elsevierStyleCrossRefs" href="#bib0490"><span class="elsevierStyleSup">38,47–50</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.1–0.2<span class="elsevierStyleHsp" style=""></span>mg/8–12<span class="elsevierStyleHsp" style=""></span>h (oral or enteral route) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Hypervolemia, lung edema, hypokalemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Hypovolemic hyponatremia, CSW \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Conivaptan<a class="elsevierStyleCrossRefs" href="#bib0490"><span class="elsevierStyleSup">38,53,54</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">20<span class="elsevierStyleHsp" style=""></span>mg i.v. in 30<span class="elsevierStyleHsp" style=""></span>min in loading dose, followed by continuous i.v. perfusion of 20–40<span class="elsevierStyleHsp" style=""></span>mg/day. Duration under 4 days \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Overcorrection, hypokalemia, orthostatic hypotension, hyperazotemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Euvolemic and hypervolemic hyponatremia. SIADH (not in moderate to severe forms). Contraindicated in CSW, high risk of vasospasm, glomerular filtration rate <30<span class="elsevierStyleHsp" style=""></span>ml/min or severe liver dysfunction \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Tolvaptan<a class="elsevierStyleCrossRefs" href="#bib0490"><span class="elsevierStyleSup">38,59,60</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15<span class="elsevierStyleHsp" style=""></span>mg on day 1, possibility of adjusting to 30–60<span class="elsevierStyleHsp" style=""></span>mg with intervals of 24<span class="elsevierStyleHsp" style=""></span>h if natremia is <135<span class="elsevierStyleHsp" style=""></span>mmol/l or the increase is <5<span class="elsevierStyleHsp" style=""></span>mmol/l/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab902819.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Drug intervention in the neurocritical patient with hyponatremia.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:60 [ 0 => array:3 [ "identificador" => "bib0305" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incidence and prognosis of dysnatremias present on ICU admission" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.C. Funk" 1 => "G. Lindner" 2 => "W. Druml" 3 => "B. Metnitz" 4 => "C. Schwarz" 5 => "P. Bauer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00134-009-1692-0" "Revista" => array:6 [ "tituloSerie" => "Intensive Care Med" "fecha" => "2010" "volumen" => "36" "paginaInicial" => "304" "paginaFinal" => "311" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19847398" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0310" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia and brain injury: historical and contemporary perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.A. Kirkman" 1 => "A.F. Albert" 2 => "A. Ibrahim" 3 => "D. Doberenz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12028-012-9805-y" "Revista" => array:6 [ "tituloSerie" => "Neurocrit Care" "fecha" => "2013" "volumen" => "18" "paginaInicial" => "406" "paginaFinal" => "416" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23212244" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0315" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical–surgical intensive care units" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H.T. Stelfox" 1 => "S.B. Ahmed" 2 => "F. Khandwala" 3 => "D. Zygun" 4 => "R. Shahpori" 5 => "K. Laupland" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc7162" "Revista" => array:5 [ "tituloSerie" => "Crit Care" "fecha" => "2008" "volumen" => "12" "paginaInicial" => "R162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19094227" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0320" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatraemia is an independent predictor of in-hospital mortality" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "I. Sturdik" 1 => "M. Adamcova" 2 => "J. Kollerova" 3 => "T. Koller" 4 => "Z. Zelinkova" 5 => "J. Payer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejim.2014.02.002" "Revista" => array:6 [ "tituloSerie" => "Eur J Intern Med" "fecha" => "2014" "volumen" => "25" "paginaInicial" => "379" "paginaFinal" => "382" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24582329" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0325" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Corona" 1 => "C. Giuliani" 2 => "G. Parenti" 3 => "D. Norello" 4 => "J.G. Verbalis" 5 => "G. Forti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0080451" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE" "fecha" => "2013" "volumen" => "8" "paginaInicial" => "e80451" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24367479" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0330" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia after aneurysmal subarachnoid hemorrhage: implications and outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.P. Saramma" 1 => "R.G. Menon" 2 => "A. Srivastava" 3 => "P.S. Sarma" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4103/0976-3147.105605" "Revista" => array:6 [ "tituloSerie" => "J Neurosci Rural Pract" "fecha" => "2013" "volumen" => "4" "paginaInicial" => "24" "paginaFinal" => "28" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23546343" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0335" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Disorders of sodium and water balance in hospitalized patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.M. Bagshaw" 1 => "D.R. Townsend" 2 => "R.C. McDermid" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12630-008-9017-2" "Revista" => array:6 [ "tituloSerie" => "Can J Anaesth" "fecha" => "2009" "volumen" => "56" "paginaInicial" => "151" "paginaFinal" => "167" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19247764" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0340" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Managing hyponatremia in neurosurgical patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.A. Kirkman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Minerva Endocrinol" "fecha" => "2014" "volumen" => "39" "paginaInicial" => "13" "paginaFinal" => "26" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24513600" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0345" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Sherlock" 1 => "E. O'Sullivan" 2 => "A. Agha" 3 => "L.A. Behan" 4 => "D. Owens" 5 => "F. Finucane" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/pgmj.2008.072819" "Revista" => array:6 [ "tituloSerie" => "Postgrad Med J" "fecha" => "2009" "volumen" => "85" "paginaInicial" => "171" "paginaFinal" => "175" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19417163" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0350" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia with intracranial disease: not often cerebral salt wasting" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.G. Verbalis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2013-4289" "Revista" => array:6 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2014" "volumen" => "99" "paginaInicial" => "59" "paginaFinal" => "62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24384014" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0355" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.G. Verbalis" 1 => "S.R. Goldsmith" 2 => "A. Greenberg" 3 => "C. Korzelius" 4 => "R.W. Schrier" 5 => "R.H. Sterns" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Med" "fecha" => "2013" "volumen" => "126" "numero" => "10 Suppl. 1" "paginaInicial" => "S5" "paginaFinal" => "S41" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0360" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cerebral salt wasting versus SIADH: what difference?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R.H. Sterns" 1 => "S.M. Silver" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1681/ASN.2007101118" "Revista" => array:6 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2008" "volumen" => "19" "paginaInicial" => "194" "paginaFinal" => "196" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18216309" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0365" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Is it cerebral or renal salt wasting?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.K. Maesaka" 1 => "L.J. Imbriano" 2 => "N.M. Ali" 3 => "E. Ilamathi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ki.2009.263" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2009" "volumen" => "76" "paginaInicial" => "934" "paginaFinal" => "938" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19641485" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0370" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brain volume regulation: osmolytes and aquaporin perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H. Pasantes-Morales" 1 => "S. Cruz-Rangel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.neuroscience.2009.11.074" "Revista" => array:6 [ "tituloSerie" => "Neuroscience" "fecha" => "2010" "volumen" => "168" "paginaInicial" => "871" "paginaFinal" => "884" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20004708" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0375" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regulatory volume decrease after swelling induced by urea in fibroblasts: prominent role of organic osmolytes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. López-Domínguez" 1 => "G. Ramos-Mandujano" 2 => "E. Vázquez-Juárez" 3 => "H. Pasantes-Morales" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11010-007-9558-7" "Revista" => array:6 [ "tituloSerie" => "Mol Cell Biochem" "fecha" => "2007" "volumen" => "306" "paginaInicial" => "95" "paginaFinal" => "104" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17684706" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0380" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cerebral salt wasting: pathophysiology, diagnosis, and treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.H. Yee" 1 => "J.D. Burns" 2 => "E.F. Wijdicks" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.nec.2009.10.011" "Revista" => array:6 [ "tituloSerie" => "Neurosurg Clin N Am" "fecha" => "2010" "volumen" => "21" "paginaInicial" => "339" "paginaFinal" => "352" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20380974" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0385" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Science review: vasopressin and the cardiovascular system. Part 1—Receptor physiology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.L. Holmes" 1 => "D.W. Landry" 2 => "J.T. Granton" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc2337" "Revista" => array:6 [ "tituloSerie" => "Crit Care" "fecha" => "2003" "volumen" => "7" "paginaInicial" => "427" "paginaFinal" => "434" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14624682" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0390" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.C. Ayus" 1 => "S.G. Achinger" 2 => "A. Arieff" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1152/ajprenal.00502.2007" "Revista" => array:6 [ "tituloSerie" => "Am J Physiol Renal Physiol" "fecha" => "2008" "volumen" => "295" "paginaInicial" => "F619" "paginaFinal" => "F624" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18448591" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0395" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia in neurological patients: cerebral salt wasting versus inappropriate antidiuretic hormone secretion" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Brimioulle" 1 => "C. Orellana-Jimenez" 2 => "A. Aminian" 3 => "J.L. Vincent" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00134-007-0905-7" "Revista" => array:6 [ "tituloSerie" => "Intensive Care Med" "fecha" => "2008" "volumen" => "34" "paginaInicial" => "125" "paginaFinal" => "131" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17952405" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0400" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The treatment of hyponatremia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.H. Sterns" 1 => "S.U. Nigwekar" 2 => "J.K. Hix" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semnephrol.2009.03.002" "Revista" => array:6 [ "tituloSerie" => "Semin Nephrol" "fecha" => "2009" "volumen" => "29" "paginaInicial" => "282" "paginaFinal" => "299" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19523575" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0405" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of endocrine disorders in the neuroscience intensive care unit" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.J. Hwang" 1 => "D.Y. Hwang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11940-013-0271-4" "Revista" => array:5 [ "tituloSerie" => "Curr Treat Options Neurol" "fecha" => "2014" "volumen" => "16" "paginaInicial" => "271" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24390813" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0410" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monitorización hemodinámica en el paciente crítico. Recomendaciones del Grupo de Trabajo de Cuidados Intensivos Cardiológicos y RCP de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Ochagavia" 1 => "F. Baigorri" 2 => "J. Mesquida" 3 => "J.M. Ayuela" 4 => "A. Ferrándiz" 5 => "X. García" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.medin.2013.10.006" "Revista" => array:6 [ "tituloSerie" => "Med Intensiva" "fecha" => "2014" "volumen" => "38" "paginaInicial" => "154" "paginaFinal" => "169" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24296336" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0415" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Valoración de la precarga y la respuesta cardiovascular al aporte de volumen" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C. Sabatier" 1 => "I. Monge" 2 => "J. Maynar" 3 => "A. Ochagavia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.medin.2011.04.005" "Revista" => array:6 [ "tituloSerie" => "Med Intensiva" "fecha" => "2012" "volumen" => "36" "paginaInicial" => "45" "paginaFinal" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21620523" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0420" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical evaluation of hyponatremia and hypovolemia in critically ill adult neurologic patients: contribution of the use of cumulative balance of sodium" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Gritti" 1 => "L.A. Lanterna" 2 => "L. Rotasperti" 3 => "M. Filippini" 4 => "S. Cazzaniga" 5 => "C. Brembilla" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00540-014-1814-x" "Revista" => array:6 [ "tituloSerie" => "J Anesth" "fecha" => "2014" "volumen" => "28" "paginaInicial" => "687" "paginaFinal" => "695" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24652158" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0425" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence and clinical demographics of cerebral salt wasting in patients with aneurysmal subarachnoid hemorrhage" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "L. Kao" 1 => "Z. Al-Lawati" 2 => "J. Vavao" 3 => "G.K. Steinberg" 4 => "L. Katznelson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11102-009-0188-9" "Revista" => array:6 [ "tituloSerie" => "Pituitary" "fecha" => "2009" "volumen" => "12" "paginaInicial" => "347" "paginaFinal" => "351" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19462244" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0430" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia following mild/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.J. Hannon" 1 => "L.A. Behan" 2 => "M.M. O’Brien" 3 => "W. Tormey" 4 => "M. Javadpour" 5 => "M. Sherlock" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1210/jc.2013-3032" "Revista" => array:6 [ "tituloSerie" => "J Clin Endocrinol Metab" "fecha" => "2014" "volumen" => "99" "paginaInicial" => "291" "paginaFinal" => "298" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24248182" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0435" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early inhibition of natriuresis suppresses symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Nakagawa" 1 => "Y. Hironaka" 2 => "F. Nishimura" 3 => "Y. Takeshima" 4 => "R. Matsuda" 5 => "S. Yamada" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000346586" "Revista" => array:6 [ "tituloSerie" => "Cerebrovasc Dis" "fecha" => "2013" "volumen" => "35" "paginaInicial" => "131" "paginaFinal" => "137" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23406891" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0440" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of hyponatremia in acute stroke stage with three-year mortality in patients with first-ever ischemic stroke" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W.Y. Huang" 1 => "W.C. Weng" 2 => "T.I. Peng" 3 => "Y.Y. Chien" 4 => "C.L. Wu" 5 => "M. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000338906" "Revista" => array:6 [ "tituloSerie" => "Cerebrovasc Dis" "fecha" => "2012" "volumen" => "34" "paginaInicial" => "55" "paginaFinal" => "62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22759703" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0445" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia in the prognosis of acute ischemic stroke" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "B. Rodrigues" 1 => "I. Staff" 2 => "G. Fortunato" 3 => "L.D. McCullough" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jstrokecerebrovasdis.2013.07.011" "Revista" => array:6 [ "tituloSerie" => "J Stroke Cerebrovasc Dis" "fecha" => "2013" "volumen" => "23" "paginaInicial" => "850" "paginaFinal" => "854" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23954607" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0450" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Analysis of risk factors for first seizure after stroke in Chinese patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Wang" 1 => "H. Jia" 2 => "C. Chen" 3 => "S. Lang" 4 => "X. Liu" 5 => "C. Xia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2013/702871" "Revista" => array:5 [ "tituloSerie" => "Biomed Res Int" "fecha" => "2013" "volumen" => "2013" "paginaInicial" => "702871" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24298553" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0455" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Young adult ischaemic stroke related acute symptomatic and late seizures: risk factors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R. Roivainen" 1 => "E. Haapaniemi" 2 => "J. Putaala" 3 => "M. Kaste" 4 => "T. Tatlisumak" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ene.12157" "Revista" => array:6 [ "tituloSerie" => "Eur J Neurol" "fecha" => "2013" "volumen" => "20" "paginaInicial" => "1247" "paginaFinal" => "1255" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23581284" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0460" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia in patients with traumatic brain injury: incidence, mechanism, and response to sodium supplementation or retention therapy with hydrocortisone" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "N. Moro" 1 => "Y. Katayama" 2 => "T. Igarashi" 3 => "T. Mori" 4 => "T. Kawamata" 5 => "J. Kojima" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.surneu.2006.11.052" "Revista" => array:6 [ "tituloSerie" => "Surg Neurol" "fecha" => "2007" "volumen" => "68" "paginaInicial" => "387" "paginaFinal" => "393" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17905062" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0465" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neuroendocrine dysfunction in the acute phase of traumatic brain injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Agha" 1 => "B. Rogers" 2 => "D. Mylotte" 3 => "F. Taleb" 4 => "W. Tormey" 5 => "J. Phillips" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Endocrinol (Oxf)" "fecha" => "2004" "volumen" => "60" "paginaInicial" => "584" "paginaFinal" => "591" ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0470" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "H.J. Schneider" 1 => "I. Kreitschmann-Andermahr" 2 => "E. Ghigo" 3 => "G.K. Stalla" 4 => "A. Agha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.298.12.1429" "Revista" => array:6 [ "tituloSerie" => "JAMA" "fecha" => "2007" "volumen" => "298" "paginaInicial" => "1429" "paginaFinal" => "1438" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17895459" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0475" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cerebral salt wasting syndrome in post-operative pediatric brain tumor patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.A. Hardesty" 1 => "T.J. Kilbaugh" 2 => "P.B. Storm" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12028-011-9618-4" "Revista" => array:6 [ "tituloSerie" => "Neurocrit Care" "fecha" => "2012" "volumen" => "17" "paginaInicial" => "382" "paginaFinal" => "387" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21822747" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0480" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Jahangiri" 1 => "J. Wagner" 2 => "M.T. Tran" 3 => "L.M. Miller" 4 => "M.W. Tom" 5 => "S. Kunwar" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Neurosurg" "fecha" => "2013" "volumen" => "11" "paginaInicial" => "1478" "paginaFinal" => "1483" ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0485" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Delayed postoperative hyponatremia after transsphenoidal surgery: prevalence and associated factors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "N.S. Hussain" 1 => "M. Piper" 2 => "W.G. Ludlam" 3 => "W.H. Ludlam" 4 => "C.J. Fuller" 5 => "M.R. Mayberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3171/2013.8.JNS13411" "Revista" => array:6 [ "tituloSerie" => "J Neurosurg" "fecha" => "2013" "volumen" => "119" "paginaInicial" => "1453" "paginaFinal" => "1460" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24053496" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0490" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice guideline on diagnosis and treatment of hyponatraemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Spasovski" 1 => "R. Vanholder" 2 => "B. Allolio" 3 => "D. Annane" 4 => "S. Ball" 5 => "D. Bichet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00134-014-3210-2" "Revista" => array:6 [ "tituloSerie" => "Intensive Care Med" "fecha" => "2014" "volumen" => "40" "paginaInicial" => "320" "paginaFinal" => "331" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24562549" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0495" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Steele" 1 => "M. Gowrishankar" 2 => "S. Abrahamson" 3 => "C.D. Mazer" 4 => "R.D. Feldman" 5 => "M.L. Halperin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "1997" "volumen" => "126" "paginaInicial" => "20" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8992919" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0500" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sérum salé hypertonique, quoi de neuf?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "N. Libert" 1 => "S. de Rudnicki" 2 => "A. Cirodde" 3 => "G. Mion" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Reanimation" "fecha" => "2010" "volumen" => "19" "paginaInicial" => "163" "paginaFinal" => "170" ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0505" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current purpose and practice of hypertonic saline in neurosurgery: a review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Thongrong" 1 => "N. Kong" 2 => "B. Govindarajan" 3 => "D. Allen" 4 => "E. Mendel" 5 => "S.D. Bergese" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.wneu.2013.02.027" "Revista" => array:6 [ "tituloSerie" => "World Neurosurg" "fecha" => "2014" "volumen" => "82" "paginaInicial" => "1307" "paginaFinal" => "1318" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23402866" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0510" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treating profound hyponatremia: a strategy for controlled correction" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.H. Sterns" 1 => "J.K. Hix" 2 => "S. Silver" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.ajkd.2010.04.020" "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2010" "volumen" => "56" "paginaInicial" => "774" "paginaFinal" => "779" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20709440" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0515" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hypernatremia in the neurologic intensive care unit: how high is too high?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "V. Aiyagari" 1 => "E. Deibert" 2 => "M.N. Diringer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcrc.2005.10.002" "Revista" => array:6 [ "tituloSerie" => "J Crit Care" "fecha" => "2006" "volumen" => "21" "paginaInicial" => "163" "paginaFinal" => "172" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16769461" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0520" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continuous hypertonic saline therapy and the occurrence of complications in neurocritically ill patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Froelich" 1 => "Q. Ni" 2 => "C. Wess" 3 => "I. Ougorets" 4 => "R. Hartl" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/CCM.0b013e31819c1933" "Revista" => array:6 [ "tituloSerie" => "Crit Care Med" "fecha" => "2009" "volumen" => "37" "paginaInicial" => "1433" "paginaFinal" => "1441" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19242317" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0525" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New trends in hyperosmolar therapy?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M.N. Diringer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MCC.0b013e32835eba30" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Crit Care" "fecha" => "2013" "volumen" => "19" "paginaInicial" => "77" "paginaFinal" => "82" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23385373" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0530" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Half-molar sodium lactate infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Ichai" 1 => "J.F. Payen" 2 => "J.C. Orban" 3 => "H. Quintard" 4 => "H. Roth" 5 => "R. Legrand" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00134-013-2978-9" "Revista" => array:6 [ "tituloSerie" => "Intensive Care Med" "fecha" => "2013" "volumen" => "39" "paginaInicial" => "1413" "paginaFinal" => "1422" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23749153" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0535" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "V.L. Feigin" 1 => "N. Anderson" 2 => "G.J. Rinkel" 3 => "A. Algra" 4 => "J. van Gijn" 5 => "D.A. Bennett" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2005" "volumen" => "20" "paginaInicial" => "CD004583" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0540" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Katayama" 1 => "J. Haraoka" 2 => "H. Hirabayashi" 3 => "T. Kawamata" 4 => "K. Kawamoto" 5 => "T. Kitahara" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/STROKEAHA.106.480038" "Revista" => array:6 [ "tituloSerie" => "Stroke" "fecha" => "2007" "volumen" => "38" "paginaInicial" => "2373" "paginaFinal" => "2375" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17585086" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0545" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.B. Bederson" 1 => "E.S. Connolly Jr." 2 => "H.H. Batjer" 3 => "R.G. Dacey" 4 => "J.E. Dion" 5 => "M.N. Diringer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/STROKEAHA.108.191395" "Revista" => array:6 [ "tituloSerie" => "Stroke" "fecha" => "2009" "volumen" => "40" "paginaInicial" => "994" "paginaFinal" => "1025" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19164800" "web" => "Medline" ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0550" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.N. Diringer" 1 => "T.P. Bleck" 2 => "J. Claude Hemphill 3rd" 3 => "D. Menon" 4 => "L. Shutter" 5 => "P. Vespa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12028-011-9605-9" "Revista" => array:6 [ "tituloSerie" => "Neurocrit Care" "fecha" => "2011" "volumen" => "15" "paginaInicial" => "211" "paginaFinal" => "240" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21773873" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0555" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia is predictable in patients with aneurysmal subarachnoid hemorrhage—Clinical significance of serum atrial natriuretic peptide" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "I. Nakagawa" 1 => "S. Kurokawa" 2 => "H. Nakase" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Acta Neurochir (Wien)" "fecha" => "2010" "volumen" => "152" "paginaInicial" => "2147" "paginaFinal" => "2152" ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0560" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vaptans: a new option in the management of hyponatremia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Aditya" 1 => "A. Rattan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4103/2229-516X.106347" "Revista" => array:6 [ "tituloSerie" => "Int J Appl Basic Med Res" "fecha" => "2012" "volumen" => "2" "paginaInicial" => "77" "paginaFinal" => "83" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23776817" "web" => "Medline" ] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0565" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Conivaptan for hyponatremia in the neurocritical care unit" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "W.L. Wright" 1 => "W.H. Asbury" 2 => "J.L. Gilmore" 3 => "O.B. Samuels" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12028-008-9152-1" "Revista" => array:6 [ "tituloSerie" => "Neurocrit Care" "fecha" => "2009" "volumen" => "11" "paginaInicial" => "6" "paginaFinal" => "13" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19003543" "web" => "Medline" ] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0570" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "T. Murphy" 1 => "R. Dhar" 2 => "M. Diringer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12028-008-9179-3" "Revista" => array:6 [ "tituloSerie" => "Neurocrit Care" "fecha" => "2009" "volumen" => "11" "paginaInicial" => "14" "paginaFinal" => "19" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19123060" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0575" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "T. Human" 1 => "A. Onuoha" 2 => "M. Diringer" 3 => "R. Dhar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcrc.2012.03.002" "Revista" => array:6 [ "tituloSerie" => "J Crit Care" "fecha" => "2012" "volumen" => "27" "paginaInicial" => "e1" "paginaFinal" => "e5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23217574" "web" => "Medline" ] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0580" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Galton" 1 => "S. Deem" 2 => "N.D. Yanez" 3 => "M. Souter" 4 => "R. Chesnut" 5 => "A. Dagal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12028-011-9525-8" "Revista" => array:6 [ "tituloSerie" => "Neurocrit Care" "fecha" => "2011" "volumen" => "14" "paginaInicial" => "354" "paginaFinal" => "360" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21409494" "web" => "Medline" ] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0585" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "X. Liu" 1 => "S. Nakayama" 2 => "M. Amiry-Moghaddam" 3 => "O.P. Ottersen" 4 => "A. Bhardwaj" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12028-009-9277-x" "Revista" => array:6 [ "tituloSerie" => "Neurocrit Care" "fecha" => "2010" "volumen" => "12" "paginaInicial" => "124" "paginaFinal" => "131" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19806476" "web" => "Medline" ] ] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0590" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Trabold" 1 => "S. Krieg" 2 => "K. Schöller" 3 => "N. Plesnila" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/neu.2008.0597" "Revista" => array:6 [ "tituloSerie" => "J Neurotrauma" "fecha" => "2008" "volumen" => "25" "paginaInicial" => "1459" "paginaFinal" => "1465" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19118456" "web" => "Medline" ] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0595" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Friedman" 1 => "J. Cirulli" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "J Crit Care" "fecha" => "2013" "volumen" => "28" ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0600" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "SALT Investigators" "etal" => false "autores" => array:3 [ 0 => "J.G. Verbalis" 1 => "S. Adler" 2 => "R.W. Schrier" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1530/EJE-10-1078" "Revista" => array:6 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2011" "volumen" => "164" "paginaInicial" => "725" "paginaFinal" => "732" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21317283" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735727/0000003900000004/v3_201509260116/S2173572715000247/v3_201509260116/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/21735727/0000003900000004/v3_201509260116/S2173572715000247/v3_201509260116/en/main.pdf?idApp=WMIE&text.app=https://medintensiva.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572715000247?idApp=WMIE" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 28 | 27 | 55 |
2024 October | 268 | 254 | 522 |
2024 September | 217 | 250 | 467 |
2024 August | 155 | 136 | 291 |
2024 July | 126 | 104 | 230 |
2024 June | 125 | 145 | 270 |
2024 May | 127 | 97 | 224 |
2024 April | 108 | 88 | 196 |
2024 March | 139 | 102 | 241 |
2024 February | 126 | 100 | 226 |
2024 January | 134 | 169 | 303 |
2023 December | 131 | 91 | 222 |
2023 November | 136 | 94 | 230 |
2023 October | 159 | 93 | 252 |
2023 September | 136 | 93 | 229 |
2023 August | 147 | 50 | 197 |
2023 July | 171 | 87 | 258 |
2023 June | 129 | 79 | 208 |
2023 May | 161 | 83 | 244 |
2023 April | 121 | 71 | 192 |
2023 March | 182 | 74 | 256 |
2023 February | 129 | 69 | 198 |
2023 January | 165 | 58 | 223 |
2022 December | 179 | 59 | 238 |
2022 November | 191 | 97 | 288 |
2022 October | 245 | 85 | 330 |
2022 September | 197 | 75 | 272 |
2022 August | 177 | 83 | 260 |
2022 July | 167 | 77 | 244 |
2022 June | 174 | 45 | 219 |
2022 May | 208 | 87 | 295 |
2022 April | 228 | 69 | 297 |
2022 March | 264 | 119 | 383 |
2022 February | 181 | 50 | 231 |
2022 January | 230 | 49 | 279 |
2021 December | 200 | 68 | 268 |
2021 November | 166 | 103 | 269 |
2021 October | 247 | 135 | 382 |
2021 September | 241 | 113 | 354 |
2021 August | 212 | 86 | 298 |
2021 July | 159 | 74 | 233 |
2021 June | 152 | 66 | 218 |
2021 May | 183 | 85 | 268 |
2021 April | 505 | 285 | 790 |
2021 March | 599 | 84 | 683 |
2021 February | 212 | 68 | 280 |
2021 January | 213 | 66 | 279 |
2020 December | 176 | 76 | 252 |
2020 November | 173 | 78 | 251 |
2020 October | 169 | 58 | 227 |
2020 September | 150 | 40 | 190 |
2020 August | 184 | 42 | 226 |
2020 July | 150 | 40 | 190 |
2020 June | 191 | 45 | 236 |
2020 May | 192 | 62 | 254 |
2020 April | 135 | 55 | 190 |
2020 March | 104 | 31 | 135 |
2020 February | 369 | 111 | 480 |
2020 January | 160 | 58 | 218 |
2019 December | 262 | 84 | 346 |
2019 November | 317 | 92 | 409 |
2019 October | 352 | 52 | 404 |
2019 September | 242 | 86 | 328 |
2019 August | 262 | 85 | 347 |
2019 July | 202 | 65 | 267 |
2019 June | 147 | 42 | 189 |
2019 May | 214 | 77 | 291 |
2019 April | 125 | 66 | 191 |
2019 March | 160 | 71 | 231 |
2019 February | 127 | 71 | 198 |
2019 January | 143 | 74 | 217 |
2018 December | 247 | 101 | 348 |
2018 November | 322 | 120 | 442 |
2018 October | 145 | 66 | 211 |
2018 September | 124 | 24 | 148 |
2018 August | 125 | 24 | 149 |
2018 July | 60 | 29 | 89 |
2018 June | 76 | 35 | 111 |
2018 May | 42 | 9 | 51 |
2018 April | 57 | 16 | 73 |
2018 March | 51 | 9 | 60 |
2018 February | 43 | 25 | 68 |
2018 January | 73 | 21 | 94 |
2017 December | 64 | 20 | 84 |
2017 November | 69 | 34 | 103 |
2017 October | 69 | 18 | 87 |
2017 September | 79 | 20 | 99 |
2017 August | 57 | 36 | 93 |
2017 July | 91 | 20 | 111 |
2017 June | 87 | 38 | 125 |
2017 May | 118 | 24 | 142 |
2017 April | 71 | 32 | 103 |
2017 March | 92 | 53 | 145 |
2017 February | 148 | 74 | 222 |
2017 January | 27 | 27 | 54 |
2016 December | 87 | 16 | 103 |
2016 November | 145 | 33 | 178 |
2016 October | 164 | 28 | 192 |
2016 September | 199 | 27 | 226 |
2016 August | 296 | 38 | 334 |
2016 July | 57 | 21 | 78 |
2015 December | 2 | 0 | 2 |